

Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Please complete application in full, sign and date, then fax to: 877-427-7290

Or email to: ViatrisPAP@viatris.com

- The PAP Application must be complete to be reviewed for patient program eligibility. Please ensure all areas of the form are completed in full, including all signatures.
- To be considered for the Viatris Patient Assistance Program, all applicants must satisfy the following requirements and eligibility criteria:
 - o Applicants qualify for the program financial requirements.
 - Applicants must be a current United States resident (includes U.S Territories).
 - Applicants must be Uninsured.
 - The requested product must be prescribed by a licensed U.S. healthcare professional for a Food and Drug Administration (FDA) approved indication.
- Each applicant will be individually assessed for program eligibility based on the information provided within this application.
- Applicants will only be evaluated for eligibility upon receipt of a completed and signed Viatris Patient Assistance Program (PAP) Application.



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Patient Information		
Name: First Last	Date of Birth: /	/ SSN:
First Last Address*	City:	Day Year (Required) State: ZIP:
Home Phone: Cell Phone:	Patient Email Address:	
Preferred Contact: Cell Phone Home Phone Email Best Tin	ne to Call: Morning Aftern	oon Evening Gender:
Insurance: Uninsured Commercial Government O	her	
Insurance Name: Insurance ID Number:		*No PO Boxes Accepted
Prescriber Information		
Prescriber Name:	Presci	riber NPI:
Facility Name:	State	License #:
Facility Address:	City:	State: ZIP:
Primary Office Contact:		Fax Number:
Phone Number: Office Contact Email:		
Prescriber Shipping Address (Only complete if shipping	address is different than	address listed above)
Prescriber Name:	Facil	ity Name:
Shipping Address:	City:	State: ZIP:
Shipment Contact Name:		
Phone Number: Contact Email:		



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Ohio Prescriber Mandatory Subsection (Select an option below, complete the related fields, then sign & date)!

MANDATORY SUBSECTION FOR ALL OHIO HCPs

a Terminal license allo information www.phare	I Distributor of Dangerous Drugs ("TDDD") or is e ows a business entity to receive, purchase, and n on TDDD licensing requirements for prescriber	npany, may only provide prescription drugs to a prescriber whose practice is licensed as exempt from such licensure under Ohio Revised Code ("ORC") § 4729.541. A TDDD possess prescription drugs, including drug samples, for distribution to patients. For more s, please visit the Ohio Board of Pharmacy website at exemptions, please refer to section 4729.541 of the ORC. The above information is r should it be construed, as legal advice.		
Please se	lect and complete one of the following and si	gn below:		
	The practice at which I work,	, located at the address I provided above, has an active TDDD license that		
	allows me to receive and store the requested prescription drug products at this location. The TDDD license number is			
-OR-				
	The practice at which I work,licensing exemptions in ORC § 4729.541.	, located at the address I provided above, is subject to one of the TDDD		
prescriptio	•	bove is complete and accurate and attest that I can receive and store the requested se I hold an unrestricted, active TDDD license or my practice is exempt from obtaining a		
Prescriber	Signature:	Date:		
	(Original signature -and-	date required, stamped signatures not accepted)		



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8am to 5pm EST |



Product & Presci	ription Information (Select a Product & Comple	te Rx Details)
Rx Product Quantity Selection- Pl	lease indicate a selection below by adding quant	ity to complete the Prescription
Arixtra® (fondaparinux sodium)	Felbatol® (felbamate)	Pretomanid Tablets
injection, solution	400mg T 100s	200mg T 26
2.5mg/0.5mL PFS 10PK	QTY	QTY
QTY	600mg T 100s	Due stafe a ma @ LIC (by dres outline no
Smg/0.4mL PFS 10PK	QTY 600mg OS 8oz	Proctofoam® HC (hydrocortisone acetate 1% and pramoxine
7.5mg/0.6mL PFS 10PK	QTY	hydrochloride 1%)
QTY	600mg OS 32oz	110 101 10
10mg/0.8mL PFS 10PK	QTY	HC 1% 10g
QTY	Gastrocrom® (cromolyn sodium,	
Cortifoam® (hydrocortisone acetate	USP) oral concentrate	ROWASA® (mesalamine) Rectal Suspension
10%) rectal foam	100mg 5mL Oral Concentrate	60mL Rectal Susp 7s
10% 15g	96s QTY	QTY
QTY	QTY	60mL Rectal Susp 28s
Cystagon® (Cysteamine bitartrate)	Impeklo® (clobetasol propionate)	QTY
capsules	Lotion MDP 0.05%	sfROWASA® (mesalamine) Rectal
50mg C 500s	QTY	Suspension
QTY	Luxiq® (betamethasonevalerate)	60mL Rectal Susp 7s
150mg C 500s	Foam	QTY 60mL Rectal Susp 28s
QTY	0.12% 100gm	QTY
Denavir® (penciclovir) Cream	QTY	Semglee® (Insulin Glargine)
1% 5gm	0.12% 50gm	Injection
QTY	QTY	1000 IU/10mL (1 Vial)
Dipentum® (olsalazine sodium)	Miacalcin® Injection	QTY
capsule 250mg C 100s	200 IU/mL 2mL MDV 1pk	300 IU/3mL (5 PF Pens)
QTY 230Hig 6 1003	QTY	QTY
	Muse® (alprostadil) urethral	Wixela Inhub® (fluticasone
Dymista ® azelastine hydrochloride & fluticasone propionate) nasal spray		propionate and salmeterol inhalation
	250mcg Suppository 6s	powder, USP)
137/50mcg Nasal Spray 23g	500mcg Suppository 6s	100mcg/50mcg 60/lnh
QTY	QTY Southey Suppository 65	250mcg/50mcg 60/lnh
EMSAM® Transdermal System	1000mcg Suppository 6s	QTY
12 mg/24 hr Bx30	QTY	500mcg/50mcg 60/lnh
QTY	Olux® (clobetasol propionate) Foam,	QTY
6 mg/24 hr Bx30	0.05%	XULANE® (norelgestromin and
QTY	0.05% 50gm	ethinyl estradiol transdermal
TDS 9 mg/24 hr Bx30	QTY	system) TDS 0.15mg/0.035mg/QD 3s
QTY	0.05% 100gm	QTY
Evoclin ® (clindamycin phosphate) Foam, 1%		Yupelri® (revefenacin) inhalation
1% 100gm	Perforomist® (formoterol fumarate) Inhalation Solution	solution
QTY	20 mcg / 2 mL 30x1	175mcg / 3mL 30s
1% 50gm	QTY	QTY
QTY	20 mcg / 2 mL 60x1	
	QTY	



Viatris Patient Assistance Program Application | Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST



Prescription Details- Please complete all	relevant prescription details below	
Patient Name:	Patient DOB:	
Prescriber Name:	Prescrit	per NPI:
Day Supply:	Refills:	
Directions:		
Prescriber Certification and Prescription	Signature	
product I have prescribed to the applicant within this Administration (FDA) approved indication, and that I will is no longer medically necessary for this patient's treatn	istance Program Application is complete and accurate to the beapplication is based on my professional judgment of medical supervise the patient's medical treatment. I will notify Viatris Pinent. I certify that I have obtained from my patient all required formation to Viatris and their agents and representatives.	cal necessity for a Food and Drug PAP immediately if the Viatris product
and representatives to verify my patient's insurance co	nd its agents and representatives is for the sole use of Viatris overage status, to assess the patient's eligibility for participat administer the product and related services. I understand that	ion in the Viatris Patient Assistance
patient may no longer be eligible for the Program, and patient's financial and/or insurance status. I agree that mail and/or telephone. I understand that I am under no compare the status of the program	ogram at any time. I understand that if my patient's financial and I agree to immediately notify a Viatris PAP representative if Viatris PAP may contact me for additional information relating obligation to prescribe any Viatris product and that I have not relating a Viatris product. I agree that I will not sell, submit claiwided by the Program.	I become aware of changes in the g to this application either by fax, e- eceived, nor will I receive, any benefit
using the Surescripts network. Surescripts requires that	plication and enrollment process, United BioSource Corporation at Prescriber agree to comply with all Surescripts' terms and ble laws, and use of data. All Surescripts disclaimers apply.	conditions, including confidentiality,
of Viatris to use and disclose as necessary for verification	, I authorize the release of medical and/or other patient information on of patient eligibility, and to furnish any information on this for that Program duration per eligibility period is 12 months, and	orm to the insurer of the applicant for
Prescriber Certification & Prescription Signature:	(original signature required)	Date:
	(Original Signature required)	



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Patient Authorization and Agreement Signature

By signing this Authorization, I authorize each of my physicians, pharmacists, including any non-commercial pharmacy that receives my prescription ("my Prescribed Product"), and other healthcare providers (together "Healthcare Providers") and each of my health insurers, if any (together, "Insurers") to disclose my Protected Health Information, including but not limited to medical records, information related to my medical condition and treatment, my health insurance coverage, my name, address, telephone number, Social Security number, insurance plan and or group numbers (together, "Protected Health Information") to Viatris, its affiliated companies, vendors, agents, collaboration partners, and representatives (together, "Viatris") including providers of alternate sources of funding for prescription drug costs, and other service providers supporting the Viatris Patient Assistance Program (PAP) (collectively, the "Program") for the purposes described below.

Specifically, I authorize disclosure of my Protected Health Information in order to:

- I. Enroll me in, and contact me about the Program, including online support, financial assistance services, and co-pay assistance services, as applicable,
- II. Communicate with my Healthcare Providers and Insurers about benefits, coverage, and medical care, including compliance with Product treatments,
- III. Facilitate dispensing of my prescription by a non-commercial pharmacy,
- IV. Provide me with educational materials, information and services related to my treatment experience with my prescribed medication and my condition,
- V. Verify, investigate, and coordinate with my Insurers regarding my prescribed medication, and
- VI. Contact me as otherwise required or permitted by law.

Once my Protected Health Information has been disclosed to Viatris, I understand that federal privacy laws no longer protect the information. However, Viatris agrees to protect my Protected Health Information by using and disclosing it only for the purposes described in this Authorization or as permitted by law. I understand that I may refuse to sign this Authorization. My choice about whether to sign will not change the way my Healthcare Providers or Insurers treat me, but I will not have access to the Viatris Patient Assistance Program and the services provided by Viatris under the Program. If I refuse to sign the Authorization, or revoke my Authorization later, I understand that this means I will not be able to participate in or receive assistance from the Program.

I understand that my signed Authorization is valid for 5 years from the date of my signature, and that I may revoke this Authorization at any time in the future, except to the extent that actions have been taken in reliance on the Authorization. I understand that to revoke this Authorization I may mail a request to 5005 Greenbag Road Morgantown, WV 26508, fax to 877-427-7290, or by calling 888-417-5780. I understand that revoking this Authorization will end further uses and disclosure of my Protected Health Information by the parties identified above except to the extent those uses and disclosures have been made in reliance upon this Authorization as permitted by applicable law. I am entitled to receive a copy of this Authorization.

I understand that if I qualify and I am enrolled in the Program sponsored by Viatris, I will receive my Prescribed Product from Viatris only pursuant to a legally valid prescription from my health care provider. I understand that if I qualify and I am enrolled in the Program, Viatris will provide me my Prescribed Product free of charge for the duration of the enrollment period so long as I have a legally valid prescription for my Prescribed Product. I understand that I am not required to continue treatment with my Prescribed Product if I gain insurance coverage, or to receive treatment from any given provider. I understand and agree that I must notify Viatris PAP at 888-417-5780 immediately if my insurance status changes during the Program enrollment period. I understand and agree that neither I nor my Insurers, if applicable, will be charged for the supply of my Prescribed Product that I received from the Program, and that under NO circumstances may I claim reimbursement from my Insurers or any other third party for the Prescribed Product provided to me free of charge from the Program. I understand that Viatris reserves the right at any time without notice to modify or discontinue the Program and its criteria.

I understand that I am providing 'written instructions' to Viatris under the Fair Credit Reporting Act authorizing Experian on behalf of Viatris to obtain information from my credit profile or other information from Experian. I authorize Viatris and its service providers to obtain such information solely for the purpose of determining financial qualifications for the Program. I understand that I must affirmatively agree to the terms in this notice by signing below in order to proceed in the Program financial screening process.

My signature certifies that I have read and understand the above statements and agree to the outlined terms.

Patient Name (Print):	Patient Signature	: Date:	
Patient Authorized Representat	ive		
	estions, any missing documentation	ving person about this application form. This includes discussing the state on and other issues related to my enrollment, or any other treatment- rel any time by calling: 888-417-5780	
Name of Authorized Representative:		Relationship to Patient:	
Telephone Number:	Email:		
By signing below, I, the patient, allow this r	epresentative to speak on my beha	alf on any matter regarding my enrollment with the Program.	
Patient Signature:		Date:	

